Evidence map›Paper›PMID 36110101›Full record

ArticleCurrent developments in nutrition2022

Pharmacokinetics of a Single Intake of a Self-Emulsifying Drug Delivery System Containing the Triglyceride Form of DHA: A Randomized, Double-Blinded, Crossover Study.

Mariko Hayashida, Yuri Ishii, Tomoki Adachi, Rie Imai, Nobuo Uotsu, Kei Yui

Open access · goldAbstract read
In one paragraph

Article in Current developments in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mariko HayashidaResearch Institute, FANCL Corporation, Yokohama, Japan.
Yuri IshiiResearch Institute, FANCL Corporation, Yokohama, Japan.
Tomoki AdachiResearch Institute, FANCL Corporation, Yokohama, Japan.
Rie ImaiResearch Institute, FANCL Corporation, Yokohama, Japan.
Nobuo UotsuResearch Institute, FANCL Corporation, Yokohama, Japan.
Kei YuiResearch Institute, FANCL Corporation, Yokohama, Japan.
Fanuc (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The health benefits of n-3 (ω-3) PUFAs are well studied. A self-emulsifying drug delivery system (SEDDS) is expected to improve n-3 PUFA absorption. Objectives: The present study investigated how a single ingestion of a new SEDDS containing the triglyceride (TG) form of DHA (22:6n-3) (DHA/TG) would affect the plasma DHA concentration in healthy participants. Methods: Fifteen healthy participants (age: 20-65 y; BMI: 18.5-25 kg/m Results: The iAUC_DHA was significantly higher for the SEDDS capsule (147.9 ± 15.8 µg·h/mL) than for the control capsule (106.4 ± 18.1 µg·h/mL) ( Conclusions: These results suggest that a SEDDS improves the absorbability of DHA/TG in healthy participants. This indicates that SEDDS capsules would be beneficial for efficient ingestion of DHA.This trial was registered at https://www.umin.ac.jp/ctr/ as UMIN000044188.

Indexed as

absorptionbioavailabilityclinical trialdocosahexaenoic aciddrug delivery systemseicosapentaenoic acidfish oilsomega-3randomized controlled trialself-emulsifying delivery system

Identifiers

PMID36110101
PMCPMC9469889
OpenAlexW4287377052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.